• MONOWAR HUSSAIN Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004
  • ANUPAM SARMA Pratiksha Institute of Pharmaceutical Sciences, Guwahati, Assam 781026
  • SHEIKH SOFIUR RAHMAN Girijananda Chowdhury Institute of Pharmaceutical Science (GIPS), Azara, Hatkhowapara, NH-37, Guwahati, Assam 781017
  • ABDUL MATIN SIDDIQUE Annai Veilankanni’s Pharmacy College, V. G. P. Salai, Saidapet, Chennai 600015
  • TANUKU PAVANI EESWARI Koringa College of Pharmacy, Pata, Korangi, Andhra Pradesh 533461


Objective: Tuberculosis (TB) is an infectious bacterial disease caused by Mycobacterium tuberculosis which most commonly affects the lungs. TB has the highest mortality rate than any other infectious disease occurs worldwide. The main objective of the present investigation was to develop polymeric nanoparticles based drug delivery system to sustain the ethambutol (ETB) release by reducing the dose frequency.

Methods: The Preformulation studies of drug ETB were done by physical characterization, melting point determination, and UV spectrophotometric analysis. The ETB loaded nanoparticles were prepared by double-emulsion (W/O/W) solvent evaporation/diffusion technique. The prepared polymeric nanoparticles were evaluated for particle size, polydispersity index, zeta potential, drug entrapment efficiency, drug loading, drug-polymer compatibility study, surface morphology, in vitro drug release, and release kinetics.

Results: Based on the result obtained from the prepared formulations, F11 showed the best result and was selected as the optimized formulation. Optimized batch (F11) showed better entrapment efficiency (73.3%), good drug loading capacity (13.21%), optimum particle size (136.1 nm), and zeta potential (25.2 mV) with % cumulative drug release of 79.08% at the end of 24 h.

Conclusion: These results attributed that developed polymeric nanoparticles could be effective in sustaining the ETB release over 24 h. Moreover, the developed nanoparticles could be an alternate method for ETB delivery with a prolonged drug release profile and a better therapeutic effect can be achieved for the treatment of tuberculosis.

Keywords: Mycobacterium tuberculosis, Ethambutol, Eudragit, Polymeric nanoparticle


1. Gebrekristos HT, Lurie MN, Mthethwa N, Karim QA. Disclosure of HIV status: experiences of patients enrolled in an integrated TB and HAART pilot program in South Africa. Afr J AIDS Res 2009;8:1-6.
2. Golden MP, Vikram HR. Extra pulmonary tuberculosis: an overview. Am Fam Physician 2005;72:1761-8.
3. Jessy Shaji, Mahmood Sheikh. Formulation, optimization, and characterization of biocompatible inhalable D-Cycloserine-loaded alginate-chitosan nanoparticles for pulmonary drug delivery. Asian J Pharm Clin Res 2016;9:82-95.
4. Shegokar R, Al Shaal L, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Sci 2011;14:100-16.
5. Joshi JM. Tuberculosis chemotherapy in the 21 century: back to the basics. Lung India 2011;28:193-200.
6. Mitchison D, Davies G. The chemotherapy of tuberculosis: Past, present, and future. Int J Tuberc Lung Dis 2012;16:724-32.
7. Prabhu C, Jalihal, Vaibhav Rajoriya, Varsha Kashaw. Design, synthesis, and evaluation of new derivative of 1,2,4-Triazole for antimicrobial and anti-inflammatory activity. Int J Curr Pharm Res 2018;10:29-35.
8. Choudhary S, V Kusum Devi. Potential of nanotechnology as a delivery platform against tuberculosis. Curr Res Rev 2015;202:65-75.
9. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-45.
10. Bangun H, Tandiono S, Arianto A. Preparation and evaluation of chitosan-tripolyphosphate nanoparticles suspension as an antibacterial agent. J Appl Pharm Sci 2018;8:147-56.
11. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: an overview of preparation and characterization. J Appl Pharm Sci 2011;1:228-34.
12. Jessy Shajia, Mahmood Shaikha. Drug-resistant tuberculosis: recent approach in polymer based nanomedicine. Int J Pharm Pharm Sci 2016;8:1-6.
13. Mohammad Nasiruddin, Md. Kausar Neyaz, Shilpi Das. Nanotechnology-based approach in tuberculosis treatment; 2017. p. 1-12.
14. Praveen Sivadasu, Gowda DV, Siddaramaiah H, Hemalatha H. Ziprasidone hydrochloride loaded nanostructured lipid carriers (NLCs) for intranasal delivery: optimization and in vivo studies. Int J Appl Pharm 2020;12:31-41.
15. Nagavarma BVN, Yadav H, Ayaz A, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharm Clin Res 2012;5:16-23.
16. Iqbal M, Zafar N, Fessi H, Elaissari A. Double emulsion solvent evaporation techniques used for drug encapsulation. Int J Pharm 2015;496:173-90.
17. Yu X, Trase I, Ren M, Duval K, Guo X, Chen Z. Design of nanoparticle-based carriers for targeted drug delivery. J Nanomater 2016. Doi:10.1155/2016/1087250
18. Jiang J, Oberdorster G, Biswas P. Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. J Nanopart Res 2009;11:77-89.
19. Mourdikoudis S, Pallares RM, Thanh NTK. Characterization techniques for nanoparticles: Comparison and complementarity upon studying nanoparticle properties. Nanoscale 2018;10:12871-934.
20. Chaurasia G. A review on pharmaceutical preformulation studies in formulation and development of new drug molecules. Int J Pharm Sci Res 2016;7:2313-20.
21. Kotila OA, Olaniyi OO, Adegoke AO, Babalola CP. Experimental determination of the physicochemical properties of lumefantrine. Afr J Med Sci 2013;42:209-14.
22. Indian Pharmacopoeia. Vol. 1. Indian Pharmacopoeia Commission; 2010.
23. Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog Polym Sci 2011;36:887-913.
24. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 2010;75:1-18.
25. Lee YS, Johnson PJ, Robbins PT, Bridson RH. Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study. Eur J Pharm Biopharm 2013;83:168-73.
26. Ravi Kumar MN. Nano and microparticles as controlled drug delivery devices. J Pharm Sci 2000;3:234-58.
27. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 2008;69:445-53.
28. Saikia C, Hussain A, Ramteke A, Sharma HK, Maji TK. Cross linked thiolated starch coated Fe3O4 magnetic nanoparticles: Effect of montmorillonite and cross-linking density on drug delivery properties. Starch-Starke 2014;66:760-71.
29. Das S, Das MK. Synthesis and characterization of thiolated jackfruit seed starch as a colonic drug delivery carrier. Int J Appl Pharm 2019;11:53-62.
30. Kandav G, Bhatt DC, Jindal DK. Formulation and evaluation of allopurinol loaded chitosan nanoparticles. Int J Appl Pharm 2019;11:49-52.
31. Khaira R, Sharma J, Saini V. Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride. Sci World J 2014. Doi:10.1155/2014/560962
32. Tripathi A, Gupta R, Saraf SA. PLGA nanoparticles of anti-tubercular drug: drug loading and release studies of a water-insoluble drug. Int J Pharmtech Res 2010;2:2116-23.
33. Bohrey S, Chourasiya V, Pandey A. Polymeric nanoparticles containing diazepam: preparation, optimization, characterization, in vitro drug release and release kinetic study. Nano Converg 2016;3:3-9.
34. D’Souza S. A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharm 2014;304757:1-12.
35. Chourasiya V, Bohrey S, Pandey A. Formulation, optimization, characterization and in vitro drug release kinetics of atenolol loaded PLGA nanoparticles using 33 factorial design for oral delivery. Mater Discovery 2016;5:1-13.
36. Singhvi G, Singh M. Review: In vitro drug release characterization models. Int J Pharm Sci Studies Res 2011;2:77-84.
37. Muthu MS, Muthu S. Pharmaceutical stability aspects of nanomedicines. Nanomedicine 2009;4:857-60.
38. Sharma D, Maheshwari D, Philip G. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using box-behnken design: in vitro and in vivo evaluation. Biomed Res Int 2014;156010:1-14.
39. Mona Qushwy, Ali Nasr. Solid lipid nanoparticles as nano drug delivery carriers: preparation, characterization and application. Int J Appl Pharm 2020;12:1-9.
40. Indian Pharmacopoeia; 1996.
41. [Last accessed on 10 Dec 2019]
42. [Last accessed on 10 Dec 2019]
43. Christopher J Ferguson. An effect size primer: a guide for clinicians and researchers. Professional Psychol: Res Practice 2009;40:532-8.
44. [Last accessed on 10 Dec 2019]
45. JN Ravi Varma, T Santosh Kumar, B Prasanthi, J Vijaya Ratna. Formulation and characterization of pyrazinamide polymeric nanoparticles for pulmonary tuberculosis: efficiency for alveolar macrophage targeting. Indian J Pharm Sci 2015;77:258-66.
46. Yi Yan Yang, Tai-Shung Chung, Ngee Ping Ng. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 2001;22:231-41.
47. Navneet Sharma, Parshotam Madan, Senshang Lin. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a co-surfactant study. Asian J Pharm Sci 2016;11:404-16.
48. Deepak Sharma. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using box-behnken design: in vitro and in vivo evaluation. BioMed Res Int 2014.
49. H Chikaura. Effect of particle size on biological response by human monocyte-derived macrophages. Biosurface Biotribol 2016;2:18-25.
50. Lisbeth Ilium, SS Davis, CG Wilson, NW Thomas, M Frier, JG Hardy. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int J Pharm 1982;12:135-46.
51. Pimchanok Witayaudom, Utai Klinkesorn. Effect of surfactant concentration and solidification temperature on the characteristics and stability of nanostructured lipid carrier (NLC) prepared from rambutan (Nephelium lappaceum L.) kernel fat. J Colloid Interface Sci 2017;505:1082-92.
52. Yuta Nakatuka, Hideto Yoshida, Kunihiro Fukui, Mitsuharu Matuzawa. The effect of particle size distribution on effective zeta-potential by use of the sedimentation method. Adv Powder Technol 2015;26:650-6.
53. Karim S Shalaby. Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks. Int J Nanomed 2014;9:4953-64.
54. Y Dastagiri Reddy, D Dhachinamoorthi, KB Chandra Sekhar. Formulation and in vitro evaluation of antineoplastic drug loaded nanoparticles as drug delivery system. Afr J Pharm Pharmacol 2013;7:1592-604.
55. DV Gowda, Vishnu Datta M, Meenakshi S, Siddaramaiah H, Vishal Kumar Gupta N. Formulation and evaluation of dry powders containing anti tuberculosis drugs for pulmonary delivery. Indo Am J Pharm Res 2013;3:1239-48.
56. Devina Verma. Design expert assisted nanoformulation design for co-delivery of topotecan and thymoquinone: optimization, in vitro characterization and stability assessment. J Mol Liquids 2017;242:382-94.
57. Pedro Fonte. Effect of cryoprotectants on the porosity and stability of insulin-loaded PLGA nanoparticles after freeze-drying. Biomatter 2012;2:329-39.
58. Dustin L Cooper, Sam Harirforoosh. Design and optimization of PLGA-based diclofenac loaded nanoparticles. PLOS One 2014;9:e87326.
59. Suvakanta Dash, Padala Narasimha Murthy, Lilakanta Nath, Prasanta Chowdhury. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharm Drug Res 2010;67:217-23.
60. Stability testing of new drug substances and products Q1A (R2). ICH harmonised tripartite guideline; 2013.
50 Views | 43 Downloads
How to Cite
HUSSAIN, M., SARMA, A., RAHMAN, S. S., SIDDIQUE, A. M., & EESWARI, T. P. (2020). FORMULATION AND EVALUATION OF ETHAMBUTOL POLYMERIC NANOPARTICLES. International Journal of Applied Pharmaceutics, 12(4), 207-217.
Original Article(s)